Market Research Report : Oncology pharmaceuticals market in india 2014 - Sample

1
Oncology Pharmaceuticals Market-India
August 2011
Oncology Pharmaceuticals Market in India
September 2014

2
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2014.PPT
Drivers:
 Increasing number of cancer cases
 Changes in the treatment scenario
 Development of alternative cancer therapies
 Increase in cancer insurances
 Increase in FDI
Drug regulation and patents
Oncology pharmaceuticals market in India is valued at INR x bn in 20—
Fourth largest in volume, eighth largest in value in the world market
Market is expected to grow at a CAGR of y% from20-----
Challenges:
Increased competition
Drug patents problem
Drug Portfolio management
Government Initiatives
Reforms in tax structure
Reduction in drug prices
Public –Private Partnership (PPP) programmes
Drug control programmes
Phases of clinical trial
Approval and licensing of drugs
Patents
Competition
Highly fragmented market with large number of players
Major public players in the market include Company A,Company B, Company C, Company D, Company E, Company F, Company G, Company H, Company I, Company J
Major private companies include Company K, Company L, Company M
Drivers and Challenges
Market
Executive Summary

3
•Macro-Economic Indicators
•Introduction
•Market Overview
•Export-Import
•Market Value Chain
•Drivers & Challenges
•Government Initiatives
•Regulations
•Competitive Landscape
•Recent Developments
•Strategic Recommendations
•Appendix

4
Economic Indicators (1/3)
11
12
13
14
15
INR tn
Q4
c4
b4
a4
Q3
c3
b3
a3
Q2
d2
c2
b2
a2
Q1
d1
c1
b1
a1
2010-11 2011-12 2012-13 2013-14
GDP at Factor Cost: Quarterly
Inflation Rate: Monthly
-2
-1
0
1
2
q
Aug 2013 - Sep 2013
r
Jul 2013 - Aug 2013 Sep 2013 - Oct 2013
p
Nov 2013 - Dec 2013
t
Oct 2013 - Nov 2013
%
s

5
Indian oncology pharma market has grown enormously over
the last few years
•Fourth largest in volume, eighth largest in
value in the world market
•Expected to reach INR y bn in 20--
•Cancer is the second largest cause of death in
the country
•According to the National Cancer Registry
Program (NCRP) there are z mn cancer
patients at any point of time
•There occurs X cancer related deaths each
year
•Oral and lung cancer are the most common in
males, while in females, cervical, followed by
breast and ovarian cancer are the most
common
•Availibilty of xx oncologists per yy people in
India
Indian market-overview Market size
Source:
Increase in Cancer Cases
0
200
400
600
800
1,000
1,200
In ‘000
20--
x
20--e
n%
y
0
10
20
30
40
50
INR unit
20-- 20-- 20--e 20--e 20--e 20--e 20--e
m%
g
f
e
d
b c a

6
A huge volume of cancer drugs is exported to many
countries…
• Highly fragmented market with many domestic
manufacturers lead to huge volume of exports
• India currently exports to more than 115 countries
• Between 20-- - 20-- and 20-- - 20-- the value of export
of oncology pharmaceuticals rose by m%
• Country A accounted for the highest exports in 20-- -
20-- while Country B ranked highest in 20-- - 20--
Exports of Oncological Pharmaceuticals Total Exports
Exports – Region wise (20-- - 20--) Exports – Region wise (20-- - 20--)
0
1,000
2,000
3,000
4,000
INR units
20– to 20--
e2
20–to 20--
e1
P%
e5
20– to 20--
e4
20– to 20--
e3
20– to 20--
Note: All figures Source: Ministry of Commerce: Export-Import Data Bank are for financial year
D1%
C1%
E1%
G1%
B1%
A1%
E2%
G2%
D2%
A2%
B2%
F2%
Country F
Country D
Country E
Country G
Country C
Country B
Country A

7
Drivers & Challenges - Summary
Drivers
Increasing number of cancer cases
Changes in the treatment scenario
Development of alternative cancer therapies
Increase in cancer insurances
Increase in the amount of FDI
Challenges
Increased competition
Drug patent problems
Drug portfolio management
Lack of affordability

8
Government initiatives
Reforms in tax structure
Public-Private-partnership (PPP) projects
Cancer control programmes
Reduction in drug prices
Government Initiative

9
SAMPLE
Porter’s Five Forces Analysis
Competitive Rivalry
•Texttext texttext texttext texttext texttext texttext texttext
Bargaining Power of Buyers
Threat of New Entrants
Impact Low to Medium
Impact Medium to High
Impact
High
Bargaining Power of Suppliers
Impact Low to Medium
Threat of Substitutes
Impact Low

10
SAMPLE
Competitive Benchmarking (1/5)
Public Trading Comparables (FY 2013) – Top 3 Companies
Company A
Company B
Company C
Market Capitalization (INR mn)
Value
Value
Value
Share Price (INR)
Value
Value
Value
EV/EBITDA (INR mn)
Value
Value
Value
EV/Revenue (INR mn)
Value
Value
Value
PE Ratio
Value
Value
Value
Note: Top 3 Public companies based on the Market Capitalization, Share Price and PE ratio is as of 18/05/2014

11
SAMPLE Key Ratios of Top 3 Companies – Operational Basis (FY 20--) (1/3)
Competitive Benchmarking (1/4)
-30
-20
-10
0
10
%
Player C
q3
Player B
p2 q2
Player A
p1 q1
Operating Margin Net Margin
• X
• X

12
Public: Domestic Company – Company A (1/3)
Key People
Products and Services
Company Information
Offices and Centres – India
Corporate Address
X Road
Bangalore
Tel No.
+91 xx xxxxx xxxxx
Fax No.
+91 xx xxxxx xxxxx
Website
www.ppp.com
Year of Incorporation
19--
Ticker Symbol
xxxxxx
Stock Exchange
NNN
Name
Designation
Person M
Founder
Person N
CFO
Person O
Head
Person Q
President
City A
Head Office
Source:
Category
Products/Services
Pharmaceutical
CVD, oncology, CNS, respiratory, dermatology, orthopedics, nutritional, urology, anti-infectives
Molecule Development
Infectious diseases, metabolic diseases, inflammatory/respiratory diseases, and oncology

13
Source:
Key Ratios
Financial Summary
Public: Domestic Company – Company B (2/3)
• The company incurred a net loss of INR xx mn in FY 20--, as
compared to net profit of INR yy mn in FY 20--
• The company reported total income of INR xx bn in FY 20--,
registering an increase of yy per cent over FY 20--
• The company earned an operating margin of x per cent in FY 20-- a
decrease of y percentage points over FY 20--
• The company reported debt to equity ratio of x in FY 20--, an
increase of y per cent over FY 20--
Financial Summary
Profit / Loss
Revenue
Profit
INR mn
p
n
0
-m
Revenue
INR mn
0
20--
t
p
20--
s
o
20--
r
n
20--
q
m
10,000
5,000
Indicators Present Value
Market Capitalization (INR) X units
Total Enterprise Value (INR) Y units
EPS (INR) Z units
PE Ratio (Absolute) A
Particulars y-o-y change 20-- 20-- 20-- 20--
Profitability Ratios
Operating Margin
Net Margin
Profit Before Tax Margin
Return on Equity
Return on Capital Employed
Return on Working Capital
Return on Assets
Return on Fixed Assets
Cost Ratios
Operating costs (% of Sales)
Administration costs (% of
Sales)
Interest costs (% of Sales)
Liquidity Ratios
Current Ratio
Cash Ratio
Leverage Ratios
Debt to Equity Ratio
Debt to Capital Ratio
Interest Coverage Ratio
Efficiency Ratios
Fixed Asset Turnover
Asset Turnover
Current Asset Turnover
Working Capital Turnover
Capital Employed Turnover
Improved Decline
Financial Snapshot

14
Public: Domestic Company – Company C (3/3)
y
x
20--
z y
x
20--
z y
x
20--
z
y
x
20--
z
m n o
Key Business Segments
20--
z
y
x
20--
z
y
x
20--
z
y
x
20--
z
y
x
x y z
Key Geographic Segments
Source:
Key Recent Developments
Description News
Overview
• Company A is an integrated research based company that produces a wide range of generic medicines
• Serves customers in over 100 countries with manufacturing facilities in several countries
Oncology Pharmaceuticals • Products include include Product 1 and Product 2
Key Initiatives
• Is making consistent effort for continual improvement in rural areas with respect to accessibility of
medicines

15
Thank you for the attention
About Netscribes, Inc.
Netscribes, Inc. is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes, Inc. is a one-stop shop designed to fulfil clients’ profitability and growth objectives.
Oncology Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Series.
For any queries or customized research requirements, contact us at:
Disclaimer: This report is published for general information only. Although high standards have been used in the preparation, “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes and prior permission is required for guidelines on reproduction.
Phone: +91 22 4098 7600
E-Mail: info@netscribes.com

Market Research Report : Oncology pharmaceuticals market in india 2014 - Sample

Recommandé

Recommandé

Contenu connexe

Plus de Netscribes, Inc.

Plus de Netscribes, Inc. (20)

Dernier

Dernier (20)

Market Research Report : Oncology pharmaceuticals market in india 2014 - Sample